Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

NCT07090343 on ClinicalTrials.gov · last registry update 2025-07-29

Registered but not yet open, with 826 participants planned. Due to report 1 September 2030, alongside 5 other tracked readouts that quarter. Primary outcome, as filed: CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for HF. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Leiden University Medical Center
Sponsor type: Other
Enrollment: 826
Started: 2026-04-01
Primary completion: 2030-09-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for HF

Conditions studied

Aortic Stenosis · Heart Failure

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.